









Markets
/
Stocks
/
nasdaq-blco
/

Bausch + Lomb Corp

BLCO

17.000USD

+0.615+3.75%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

6.02BMarket Cap

LossP/E TTM



Bausch + Lomb Corp

17.000

+0.615+3.75%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Bausch + Lomb Corp

Currency: USD Updated: 2026-02-06

Key Insights

Bausch + Lomb Corp's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is high.Its valuation is considered fairly valued, ranking 83 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 17.33.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals and technicals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Bausch + Lomb Corp's Score

Industry at a Glance

Industry Ranking

83 / 205

Overall Ranking

222 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Negative

Bausch + Lomb Corp Highlights

StrengthsRisks

Bausch + Lomb Corporation is an eye health company. It operates through three segments: Vision Care, Pharmaceuticals, and Surgical. Vision Care segment includes both a contact lens and a consumer eye care business that consists of contact lens care products, over-the-counter eye drops and eye vitamins. Pharmaceuticals segment consists of generic pharmaceutical products for post-operative treatments and treatments for a number of eye conditions, such as glaucoma, eye inflammation, ocular hypertension, dry eyes and retinal diseases. Surgical segment consists of medical device equipment, consumables, instruments and technologies for the treatment of cataracts, corneal and vitreous and retinal eye conditions, which includes delivery systems, phacoemulsification equipment and other surgical instruments and devices for cataract surgery. Its brands consist of PreserVision, Biotrue, Artelac, Alaway, Mioclear, Ocuvite, ScoutPro, XIIDRA, Vyzulta, Lotemax, Prolensa, Minims, INFUSE, and many more.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 27.15% year-on-year.

Fairly Valued

The company’s latest PE is -19.71, at a medium 3-year percentile range.

Institutional Buying

The latest institutional holdings are 42.63M shares, increasing 0.03% quarter-over-quarter.

Held by Howard Marks

Star Investor Howard Marks holds 3.25M shares of this stock.

Analyst Rating

Based on 13 analysts

Hold

Current Rating

17.333

Target Price

+5.63%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Bausch + Lomb Corp is 6.40, ranking 156 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is high. Its latest quarterly revenue reached 1.28B, representing a year-over-year increase of 7.11%, while its net profit experienced a year-over-year increase of 800.00%.

Score

Industry at a Glance

Previous score

6.40

Change



Financials

5.34

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

2.53

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

8.74

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

8.12

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.28

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Bausch + Lomb Corp's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Bausch + Lomb Corp is 8.63, ranking 15 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -19.71, which is -5696.42% below the recent high of 1103.27 and -237.50% above the recent low of -66.53.

Score

Industry at a Glance

Previous score

8.63

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 83/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Bausch + Lomb Corp is 6.77, ranking 158 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 17.00, with a high of 21.00 and a low of 13.00.

Score

Industry at a Glance

Previous score

6.77

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 13 analysts

Hold

Current Rating

17.333

Target Price

+5.63%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

114

Total

Median

Average

Company name

Ratings

Analysts

Bausch + Lomb Corp

BLCO

Stryker Corp

SYK

Abbott Laboratories

ABT

Medtronic PLC

MDT

Dexcom Inc

DXCM

Zimmer Biomet Holdings Inc

ZBH

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Bausch + Lomb Corp is 7.22, ranking 42 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 17.85 and the support level at 16.16, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.63

Change

0.59

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(2)

Buy(3)

Indicators

Value

Direction

MACD(12,26,9)

-0.112

Sell

RSI(14)

52.807

Neutral

STOCH(KDJ)(9,3,3)

55.144

Buy

ATR(14)

0.432

High Vlolatility

CCI(14)

12.239

Neutral

Williams %R

39.416

Buy

TRIX(12,20)

-0.108

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(0)

Neutral(0)

Buy(6)

Indicators

Value

Direction

MA5

16.588

Buy

MA10

16.696

Buy

MA20

16.978

Buy

MA50

16.911

Buy

MA100

16.045

Buy

MA200

14.618

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Bausch Health Companies Inc

310.45M

Icahn Enterprises LP

3.50M

Deutsche Bank Securities Inc.

3.50M

+2.64%

Alberta Investment Management Corporation

3.27M

+8.58%

Oaktree Capital Management, L.P.

Star Investors

3.25M

+28.72%

GoldenTree Asset Management, LP

2.66M

+2.99%

D. E. Shaw & Co., L.P.

2.61M

Silver Point Capital, L.P.

2.56M

Fidelity Management & Research Company LLC

1.56M

+102.13%

Glenview Capital Management, LLC

Star Investors

1.55M

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Bausch + Lomb Corp is 7.06, ranking 45 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 0.61. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets. with an industry-leading ESG disclosure.